Currently, there is no consensus on the specific roles of different imaging modalities or the best targets for imaging in the clinical setting.
Cardiovascular Imaging: A Growing Field
Acute cardiovascular events result from the multifaceted relationship between a patient's atherosclerotic risk factors and local factors, such as the location, burden, metabolic and functional characteristics of atherosclerotic disease that go beyond simple lumen stenosis. [2] [3] [4] Consequently, scientific interest has moved from the degree of the lumen stenosis to investigating vessel wall structure, haemodynamic features, and the molecular and cellular mechanisms underlying atherogenesis, progression and thrombosis. Optical coherence tomography (OCT); coronary intravascular ultrasound (IVUS); coronary CT angiography; high-resolution MRI; nuclear imaging such as PET and spectroscopy; molecular imaging by contrast media for OCT, ultrasound and MRI; and fusion imaging have the potential to broaden our structural, functional and biological understanding of plaque. [5] [6] [7] [8] [9] Likewise, computational flow dynamics allows the appraisal of the biomechanical factors of atherosclerosis. potential responsiveness to these agents. 13 However, this may not provide sufficient evidence to change clinical practice, since it should be supported by large-scale trials possibly assessing both imaging and clinical endpoints. This would allow a rationalisation of cardiovascular drug development.
Imaging and Theranostics in Cardiovascular Pharmacotherapy 16 The scientific community must also consider the setbacks that hinder the translatability of the existing imaging techniques, particularly for radiation, contrast media exposure and high costs.
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Theranostics
Considering the complexity, rationalising cardiovascular drug development and moving towards personalised, preventive and therapeutic medicine should be a mainstay of future research.
Theranostics could be used to help bridge the gap between experimental evidence and large-scale trials.
Theranostics combines imaging and therapeutic functions by using imaging-based therapeutic delivery systems. Studies have employed nanoparticles for contrast agent-assisted diagnostic imaging, therapeutic delivery and subsequent evaluation of therapeutic efficacy.
Theranostics is a result of advances in multiple natural and material sciences, particularly nanotechnology. Primarily used in oncology, it has been gradually applied to early and late atherosclerotic lesions with encouraging results. 21 In theranostics, drug delivery and subsequent action in a region of interest is controlled by an external energy fieldmostly ultrasound, light, or a magnetic field -in an attempt to minimise systemic and local effects. 
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Based on a similar principle, MRI has been used for site-specific vascular intervention. A magnetic field attracts and activates metallic nanoparticles with a protective coating to detect and inhibit inflammatory processes in atherosclerosis. 30, 31 In another study, gold nanorods were synthesised to diagnose and attenuate macrophage activity and release by delivering photodynamic therapy. 32, 33 Similarly, paramagnetic nanoparticles have delivered anti-proliferative drugs and micro-RNA to inhibit either proliferation of smooth muscle cells or angiogenesis. 34, 35 The development of imaging systems specifically designed for theranostic use will improve its potential. However, unsolved issues related to potential harmful exposures and costs need to be addressed before application of theranostics in extended human research and clinical practice could be feasible.
Conclusion
Cardiovascular imaging of atherosclerosis is a useful instrument, which corroborates and expands pathophysiological evidence on cardiovascular disease, and provides proof of concepts for medical therapy. It might also be used to anticipate the beneficial effect on clinical endpoints and the responsiveness to medical therapy and can represent surrogate endpoints in clinical trials. Theranostics could further translate experimental evidence and large-scale trials assessing clinical endpoints, rationalising cardiovascular drug development and paving the way to more personalised medicine.
